CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function

Keyur Thakar; Aileen Novero; Arundhati Das; Adriana Lisinschi; Bella Mehta; Tauseef Ahmed; Delong Liu

doi:10.1186/2050-7771-2-12

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function

Biomark Res. 2014 Jun 23:2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014.

Authors

Keyur Thakar¹, Aileen Novero¹, Arundhati Das¹, Adriana Lisinschi¹, Bella Mehta¹, Tauseef Ahmed¹, Delong Liu²

Affiliations

¹ Division of Hematology & Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA.
² Henan Tumor Hospital, Zhengzhou University, Zhengzhou 450003, China.

Abstract

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present two cases of young male patients with atypical presentation of Hodgkin lymphoma with severe abnormal liver function. Patients showed excellent response to cyclophosphamide, etoposide, procarbazine and prednisone (CEPP regimen).

Keywords: CEPP regimen; Hodgkin lymphoma; extranodal lymphoma.

Publication types

Case Reports